Journal Article
. 2018 Mar;25(6).
doi: 10.1245/s10434-018-6411-z.

The 21-Gene Recurrence Score in Male Breast Cancer

Gulisa Turashvili 1 Monica Gonzalez-Loperena 1 Edi Brogi 1 Maura Dickler 2 Larry Norton 2 Monica Morrow 3 Hannah Y Wen 4 
  • PMID: 29520654
  •     39 References
  •     3 citations


Background: Given the limited data, systemic treatment of male breast cancer has been extrapolated from female patients. The 21-gene recurrence score (RS) assay estimates the risk of distant recurrence and chemotherapy benefit in early-stage, ER+/HER2- female breast cancer. We assessed the association between RS and type of treatment in male breast cancer.

Methods: We identified male patients with ER+/HER2- breast cancer and available RS results treated at our institution in 2006-2016. We collected data on clinicopathologic features, treatment, and outcome. The Institutional Review Board approved the study.

Results: The study cohort consists of 38 male breast cancer patients with a median age of 70 years. Median tumor size was 1.6 cm, and 81.6% (31) were node-negative. RS was low (≤ 17) in 26 (68.4%) cases, intermediate (18-30) in 9 (23.7%) cases, and high (≥ 31) in 3 (7.9%) cases, comparable to that in female patients at our institution. All patients underwent total mastectomy, and one received radiotherapy. Thirty-four (89.5%) patients received adjuvant endocrine therapy, mostly tamoxifen (81.6%; 31). Five (13.2%) patients with intermediate or high RS were treated with adjuvant chemotherapy. No locoregional recurrence was observed, and one patient developed distant recurrence (median follow-up 34 months).

Conclusions: The RS distribution in male breast cancers was similar to that in females treated at our institution. With limited follow-up, patients with low RS were spared chemotherapy and did not develop recurrence. Our results suggest that the RS may have a clinical utility in male breast cancer patients.

A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer.
Soonmyung Paik, Steven Shak, +12 authors, Norman Wolmark.
N Engl J Med, 2004 Dec 14; 351(27). PMID: 15591335
Highly Cited.
Oncotype-DX recurrence score distribution in breast cancer patients with BRCA1/2 mutations.
R Lewin, A Sulkes, +11 authors, R Yerushalmi.
Breast Cancer Res Treat, 2016 May 27; 157(3). PMID: 27225387
Gene expression profiling of primary male breast cancers reveals two unique subgroups and identifies N-acetyltransferase-1 (NAT1) as a novel prognostic biomarker.
Ida Johansson, Cecilia Nilsson, +8 authors, Ingrid Hedenfalk.
Breast Cancer Res, 2012 Feb 16; 14(1). PMID: 22333393    Free PMC article.
The effects of oncotype DX recurrence scores on chemotherapy utilization in a multi-institutional breast cancer cohort.
Foluso O Ademuyiwa, Austin Miller, +5 authors, Sunil Badve.
Breast Cancer Res Treat, 2011 Jan 05; 126(3). PMID: 21197567
Prospective Validation of a 21-Gene Expression Assay in Breast Cancer.
Joseph A Sparano, Robert J Gray, +28 authors, George W Sledge.
N Engl J Med, 2015 Sep 29; 373(21). PMID: 26412349    Free PMC article.
Highly Cited.
The 21-gene recurrence score assay impacts adjuvant therapy recommendations for ER-positive, node-negative and node-positive early breast cancer resulting in a risk-adapted change in chemotherapy use.
W Eiermann, M Rezai, +13 authors, J Blohmer.
Ann Oncol, 2012 Nov 09; 24(3). PMID: 23136233    Free PMC article.
21-Gene Recurrence Score and Locoregional Recurrence in Node-Positive/ER-Positive Breast Cancer Treated With Chemo-Endocrine Therapy.
Eleftherios P Mamounas, Qing Liu, +14 authors, Norman Wolmark.
J Natl Cancer Inst, 2017 Jan 27; 109(4). PMID: 28122895    Free PMC article.
Genotypic and phenotypic analysis of familial male breast cancer shows under representation of the HER2 and basal subtypes in BRCA-associated carcinomas.
Siddhartha Deb, Nicholas Jene, Kconfab Investigators, Stephen B Fox.
BMC Cancer, 2012 Nov 14; 12. PMID: 23146383    Free PMC article.
Prognostic factors in male breast cancer: a population-based study.
José Pablo Leone, Ariel Osvaldo Zwenger, +4 authors, Rohit Bhargava.
Breast Cancer Res Treat, 2016 Apr 04; 156(3). PMID: 27039306
Prospective transGEICAM study of the impact of the 21-gene Recurrence Score assay and traditional clinicopathological factors on adjuvant clinical decision making in women with estrogen receptor-positive (ER+) node-negative breast cancer.
J Albanell, A González, +17 authors, A Lluch.
Ann Oncol, 2011 Jun 10; 23(3). PMID: 21652577
The 21-gene recurrence score assay (Oncotype DX™) in estrogen receptor-positive male breast cancer: experience in an Israeli cohort.
Tal Grenader, Rinat Yerushalmi, +4 authors, David B Geffen.
Oncology, 2014 Jun 28; 87(1). PMID: 24970679
Prospective multicenter study of the impact of the 21-gene recurrence score assay on medical oncologist and patient adjuvant breast cancer treatment selection.
Shelly S Lo, Patricia B Mumby, +8 authors, Kathy S Albain.
J Clin Oncol, 2010 Jan 13; 28(10). PMID: 20065191
Highly Cited.
Impact of the 21-gene recurrence score assay compared with standard clinicopathologic guidelines in adjuvant therapy selection for node-negative, estrogen receptor-positive breast cancer.
Jessica F Partin, Eleftherios P Mamounas.
Ann Surg Oncol, 2011 May 04; 18(12). PMID: 21537874
Gender differences in breast cancer: analysis of 13,000 breast cancers in men from the National Cancer Data Base.
Jon M Greif, Christopher M Pezzi, +2 authors, Marlene Zuraek.
Ann Surg Oncol, 2012 Jul 07; 19(10). PMID: 22766989
Association Between Use of the 21-Gene Recurrence Score Assay and Receipt of Chemotherapy Among Medicare Beneficiaries With Early-Stage Breast Cancer, 2005-2009.
Michaela A Dinan, Xiaojuan Mi, +2 authors, Lesley H Curtis.
JAMA Oncol, 2015 Aug 28; 1(8). PMID: 26313372
Twenty-one-gene recurrence score assay in BRCA-associated versus sporadic breast cancers: Differences based on germline mutation status.
Payal D Shah, Sujata Patil, +3 authors, Mark E Robson.
Cancer, 2016 Feb 10; 122(8). PMID: 26859126
Use of 21-gene recurrence score assay to individualize adjuvant chemotherapy recommendations in ER+/HER2- node positive breast cancer-A National Cancer Database study.
Prema P Peethambaram, Tanya L Hoskin, +3 authors, Judy C Boughey.
NPJ Breast Cancer, 2017 Oct 27; 3. PMID: 29067357    Free PMC article.
The Genomic Landscape of Male Breast Cancers.
Salvatore Piscuoglio, Charlotte K Y Ng, +19 authors, Jorge S Reis-Filho.
Clin Cancer Res, 2016 Mar 11; 22(16). PMID: 26960396    Free PMC article.
Pathological characterisation of male breast cancer: Results of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program.
Marijn A Vermeulen, Leen Slaets, +12 authors, Carolien H M van Deurzen.
Eur J Cancer, 2017 Mar 16; 82. PMID: 28292559
Multidisciplinary meeting on male breast cancer: summary and research recommendations.
Larissa A Korde, Jo Anne Zujewski, +13 authors, Fatima Cardoso.
J Clin Oncol, 2010 Mar 24; 28(12). PMID: 20308661    Free PMC article.
Highly Cited.
Adjuvant therapy with tamoxifen compared to aromatase inhibitors for 257 male breast cancer patients.
Holm Eggemann, Atanas Ignatov, +5 authors, Serban-Dan Costa.
Breast Cancer Res Treat, 2012 Dec 12; 137(2). PMID: 23224235
Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer.
Soonmyung Paik, Gong Tang, +11 authors, Norman Wolmark.
J Clin Oncol, 2006 May 25; 24(23). PMID: 16720680
Highly Cited.
An analysis of male and female breast cancer treatment and survival among demographically identical pairs of patients.
C E Scott-Conner, P R Jochimsen, H R Menck, D J Winchester.
Surgery, 1999 Oct 16; 126(4). PMID: 10520928
Twenty-five-year follow-up of a randomized trial comparing radical mastectomy, total mastectomy, and total mastectomy followed by irradiation.
Bernard Fisher, Jong-Hyeon Jeong, +3 authors, Norman Wolmark.
N Engl J Med, 2002 Aug 23; 347(8). PMID: 12192016
Highly Cited.
Similar prevalence of founder BRCA1 and BRCA2 mutations among Ashkenazi and non-Ashkenazi men with breast cancer: evidence from 261 cases in Israel, 1976-1999.
Gabriel Chodick, Jeffery P Struewing, +2 authors, Jose Iscovich.
Eur J Med Genet, 2007 Dec 26; 51(2). PMID: 18158280    Free PMC article.
Hormone Receptor-Positive Breast Cancer Has a Worse Prognosis in Male Than in Female Patients.
Xiaoxian Li, Jing Yang, +4 authors, Limin Peng.
Clin Breast Cancer, 2017 Jun 04; 17(5). PMID: 28576631
Adjuvant systemic therapy for male breast carcinoma.
Sharon H Giordano, George H Perkins, +4 authors, Gabriel N Hortobagyi.
Cancer, 2005 Nov 05; 104(11). PMID: 16270318
Gene expression analysis reveals a different transcriptomic landscape in female and male breast cancer.
Maurizio Callari, Vera Cappelletti, +6 authors, Maria Grazia Daidone.
Breast Cancer Res Treat, 2010 Jul 14; 127(3). PMID: 20625818
Breast Cancer-Major changes in the American Joint Committee on Cancer eighth edition cancer staging manual.
Armando E Giuliano, James L Connolly, +6 authors, Gabriel N Hortobagyi.
CA Cancer J Clin, 2017 Mar 16; 67(4). PMID: 28294295
Highly Cited.
Mutation analysis of BRCA1 and BRCA2 in a male breast cancer population.
L S Friedman, S A Gayther, +5 authors, H Anton-Culver.
Am J Hum Genet, 1997 Feb 01; 60(2). PMID: 9012404    Free PMC article.
21-Gene recurrence score and locoregional recurrence in lymph node-negative, estrogen receptor-positive breast cancer.
Gulisa Turashvili, Joanne F Chou, +5 authors, Hannah Y Wen.
Breast Cancer Res Treat, 2017 Jul 14; 166(1). PMID: 28702894    Free PMC article.
The effect of Oncotype DX recurrence score on treatment recommendations for patients with estrogen receptor-positive early stage breast cancer and correlation with estimation of recurrence risk by breast cancer specialists.
Jennifer E Joh, Nicole N Esposito, +10 authors, Geza Acs.
Oncologist, 2011 Oct 22; 16(11). PMID: 22016474    Free PMC article.
Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial.
Kathy S Albain, William E Barlow, +20 authors, Breast Cancer Intergroup of North America.
Lancet Oncol, 2009 Dec 17; 11(1). PMID: 20005174    Free PMC article.
Highly Cited.
Predictive and prognostic value of the 21-gene recurrence score in hormone receptor-positive, node-positive breast cancer.
Adam M Brufsky.
Am J Clin Oncol, 2014 May 24; 37(4). PMID: 24853663    Free PMC article.
Systematic Review.
The impact of the 21-gene recurrence score assay on decision making about adjuvant chemotherapy in early-stage estrogen-receptor-positive breast cancer in an oncology practice with a unified treatment policy.
D B Geffen, S Abu-Ghanem, +6 authors, M Koretz.
Ann Oncol, 2011 Mar 03; 22(11). PMID: 21363879
Prospective Evaluation of the 21-Gene Recurrence Score Assay for Breast Cancer Decision-Making in Ontario.
Mark N Levine, Jim A Julian, +5 authors, Kathleen I Pritchard.
J Clin Oncol, 2015 Nov 26; 34(10). PMID: 26598746
The impact of the Oncotype Dx breast cancer assay in clinical practice: a systematic review and meta-analysis.
Josh J Carlson, Joshua A Roth.
Breast Cancer Res Treat, 2013 Aug 27; 141(1). PMID: 23974828    Free PMC article.
Highly Cited. Systematic Review.
Male breast cancer.
Ian S Fentiman, Alain Fourquet, Gabriel N Hortobagyi.
Lancet, 2006 Feb 21; 367(9510). PMID: 16488803
Highly Cited. Review.
Oncotype Dx recurrence score among BRCA1/2 germline mutation carriers with hormone receptors positive breast cancer.
Naama Halpern, Amir Sonnenblick, +5 authors, Luna Kadouri.
Int J Cancer, 2017 Jan 26; 140(9). PMID: 28120435
Features, Outcomes, and Management Strategies of Male Breast Cancer: A Single Institution Comparison to Well-Matched Female Controls.
Joseph Liu, Anupama Suresh, +18 authors, Robert Wesolowski.
Eur J Breast Health, 2020 Jul 14; 16(3). PMID: 32656521    Free PMC article.
Sex Disparity Observed for Oncotype DX Breast Recurrence Score in Predicting Mortality Among Patients with Early Stage ER-Positive Breast Cancer.
Fei Wang, Sonya Reid, +6 authors, Xiao-Ou Shu.
Clin Cancer Res, 2019 Nov 22; 26(1). PMID: 31748278    Free PMC article.
Characterization and prognosis of estrogen receptor-positive/progesterone receptor-negative male breast cancer: a population-based study.
Jin-Li Wei, Jia-Xin Zhang, De-Yuan Fu.
World J Surg Oncol, 2018 Dec 19; 16(1). PMID: 30558615    Free PMC article.